US02043Q1076 - Common Stock

We assign a fundamental rating of **3** out of 10 to **ALNY**. **ALNY** was compared to 609 industry peers in the **Biotechnology** industry. **ALNY** may be in some trouble as it scores bad on both profitability and health. **ALNY** is valued quite expensive, but it does show an excellent growth.

In the past 5 years **ALNY** always reported negative operating cash flow.

With an excellent **Return On Assets** value of **-13.28%**, **ALNY** belongs to the best of the industry, outperforming **87.00%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | -13.28% | ||

ROE | N/A | ||

ROIC | N/A |

ROA(3y)-26.83%

ROA(5y)-33.17%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

With an excellent **Gross Margin** value of **84.00%**, **ALNY** belongs to the best of the industry, outperforming **87.50%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | N/A | ||

PM (TTM) | N/A | ||

GM | 84% |

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-1.86%

GM growth 5YN/A

Compared to 1 year ago, **ALNY** has more shares outstanding

Compared to 5 years ago, **ALNY** has more shares outstanding

Compared to 1 year ago, **ALNY** has a worse debt to assets ratio.

Based on the Altman-Z score of **1.47**, we must say that **ALNY** is in the distress zone and has some risk of bankruptcy.

Looking at the **Altman-Z score**, with a value of **1.47**, **ALNY** is in the better half of the industry, outperforming **67.33%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | N/A | ||

Debt/FCF | N/A | ||

Altman-Z | 1.47 |

ROIC/WACCN/A

WACC11.09%

A Quick Ratio of **3.04** indicates that **ALNY** has no problem at all paying its short term obligations.

The **Quick ratio** of **ALNY** (**3.04**) is worse than **67.17%** of its industry peers.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 3.14 | ||

Quick Ratio | 3.04 |

The **Earnings Per Share** has grown by an impressive **54.70%** over the past year.

Measured over the past years, **ALNY** shows a very strong growth in **Revenue**. The Revenue has been growing by **63.09%** on average per year.

EPS 1Y (TTM)54.7%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q142.75%

Revenue 1Y (TTM)79.37%

Revenue growth 3Y67.74%

Revenue growth 5Y63.09%

Revenue growth Q2Q183.96%

Based on estimates for the next years, **ALNY** will show a very strong growth in **Earnings Per Share**. The EPS will grow by **25.37%** on average per year.

The **Revenue** is expected to grow by **32.47%** on average over the next years. This is a very strong growth

EPS Next Y58.07%

EPS Next 2Y22.44%

EPS Next 3Y23.15%

EPS Next 5Y25.37%

Revenue Next Year79.79%

Revenue Next 2Y32.67%

Revenue Next 3Y33.44%

Revenue Next 5Y32.47%

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

Besides the negative Price/Earnings Ratio, also the **Forward Price/Earnings Ratio** is negative for **ALNY**. No positive earnings are expected for the next year.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | N/A | ||

Fwd PE | N/A |

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | N/A | ||

EV/EBITDA | N/A |

A more expensive valuation may be justified as **ALNY**'s earnings are expected to grow with **23.15%** in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y22.44%

EPS Next 3Y23.15%

No dividends for **ALNY**!.

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

**ALNYLAM PHARMACEUTICALS INC**

NASDAQ:ALNY (12/8/2023, 7:00:01 PM)

After market: 170.04 0 (0%)**170.04**

**-7.22 (-4.07%) **

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap21.34B

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | N/A | ||

Fwd PE | N/A | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | -13.28% | ||

ROE | N/A | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | N/A | ||

PM (TTM) | N/A | ||

GM | 84% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.45

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | N/A | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 3.14 | ||

Quick Ratio | 3.04 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)54.7%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y58.07%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)79.37%

Revenue growth 3Y67.74%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y